Drug Profile
H 100
Alternative Names: H-100™Latest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator Hybrid Medical
- Class Anti-inflammatories; Antifibrotics
- Mechanism of Action Fibroblast growth factor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Peyronie's disease
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for phase-I development in Peyronie's-disease in USA (Topical, Gel)
- 03 May 2022 Petros Pharmaceuticals intends to pursue 505(B) pathway for H 100 for Peyronie's disease
- 08 Nov 2021 Petros Pharmaceuticals announces intention to register H 100 for Peyronie's disease in the US